RARA CRAFT DATABASE for FDA Medical Devices
510(k)K183446

FDA DEVICE FACTS

BioPlex 2200 Lyme Total

Bio-Rad Laboratories

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMarch 12, 2019PRODUCT CODELSR

Indications for use

1.Intended use(s): The BioPlex 2200 Lyme Total kit is a multiplex flow immunoassay intended for the qualitative detection of total (IgM/IgG) antibodies to Borrelia burgdorferi in human serum and plasma (EDTA, heparin). This assay should be used to test patients with history and/or symptoms of infection with B. burgdorferi. The BioPlex 2200 Lyme Total kit is intended for use with the Bio-Rad BioPlex 2200 System. All reactive and equivocal specimens should be tested with a second tier test such as Lyme IgG and IgM Western blot assays. Positive second tier results are supportive evidence of infection with B. burgdorferi. Diagnosis of Lyme borreliosis should be made based on the presence of B. burgdorferi antibodies, history, symptoms, and other laboratory data. Non-reactive first tier or negative second tier results should not be used to exclude borreliosis.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): N/A

4. Special instrument requirements: BioPlex 2200 System

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026